Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.47 |
| ▸ | CA1 | P00915 | 7/20 | 0.47 |
| ▸ | CA2 | P00918 | 7/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6141883 | 0.92 | PTGS2 (0.47) | PTGS2CA1CA2PTGS1CA12 | |
| SCHEMBL4861850 | 0.92 | PTGS2 (0.47) | PTGS2CA1CA2PTGS1CA12 | |
| SCHEMBL6141813 | 0.91 | PTGS2 (0.51) | PTGS2PTGS1KDM4E | |
| SCHEMBL6141923 | 0.91 | PTGS2 (0.51) | PTGS2PTGS1KDM4E | |
| SCHEMBL6141531 | 0.90 | KMT2A (0.48) | PTGS2CA1CA2PTGS1CA12 | |
| SCHEMBL4857021 | 0.86 | KDM4E (0.48) | KDM4E | |
| SCHEMBL4861613 | 0.86 | KDM4E (0.48) | KDM4E | |
| SCHEMBL4854733 | 0.85 | KDM4E (0.49) | KDM4E | |
| SCHEMBL4864177 | 0.85 | KDM4E (0.49) | KDM4E | |
| SCHEMBL4859624 | 0.82 | PTGS2 (0.46) | PTGS2PTGS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225075-A1 | Novel pyrimidone derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-12-04 | — | — | US | claimed |
| US-20030225075-A1 | Novel pyrimidone derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225075-A1 | Novel pyrimidone derivatives | TPMT, TYMP, TYMS | PTGS2 1692/4885CA1 4829/4885CA2 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.